Study Phase 3

Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension

Trial Information

Generic NameSelexipagProduct NameUPTRAVI®Therapeutic AreaBlood and Blood-Forming OrgansProduct ClassAntithrombotic AgentsCondition StudiedPulmonary Arterial HypertensionChemical SubgroupsN/APharmacological SubgroupsN/A
Sponsor Protocol NumberAC-065A304Enrollment34Data PartnerJohnson & Johnson% Female82.4%Mean/Median Age (Years)53.2% White82.4%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.